Positive data for Caribou Biosciences’ CB-010 candidate
CAR-T cell therapy being researched among patients with relapsed or refractory B cell non-Hodgkin lymphoma
Read More
Tag: caribou
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
- Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
